Circulating extracellular vesicles in serum carry Trop2 marker for prostate cancer liquid biopsy and clinical care
Sinawang, P. D.; Ozen, M. O.; Liu, S.; Hsu, E.-C.; Akin, D.; Ding, E.; Nolley, R.; Brooks, J. D.; Stoyanova, T.; Demirci, U.
Show abstract
Extracellular vesicles (EVs) are lipid nano-to-micro-sized vesicles increasingly identified as valuable liquid biopsy tools for medical applications. However, the heterogeneity of cargo and the lack of convenient quantification methods to characterize EVs pose challenges in identifying vesicles with specific markers. In this study, we show the isolation, characterization, detection, and quantification of a cancer-specific marker, Trop2, on circulating extracellular vesicles in serum (EV-Trop2). This work combines the unique advantages of our user-friendly isolation method with serum diagnostics to identify high-risk prostate cancer cases and predict recurrence after prostate surgery. To our knowledge, this is the first demonstration to isolate and quantify EV-Trop2 from prostate cancer patient serum to study its analytical validity and potential clinical utility as an EV-based liquid biopsy. Initial study with patient serum samples from three clinical groups: high- risk prostate cancer (n = 22), low-risk prostate cancer (n = 23), and cancer-free groups (n = 21), demonstrates the potential of this approach in distinguishing prostate cancer aggressiveness. We observed significantly different levels of EV-Trop2 expression between the high-risk and low-risk patient groups (p = 0.0015), and between high-risk patient and cancer-free groups (p < 0.0001). Furthermore, employing machine learning algorithms, EV-Trop2 was shown to enhance classifier metrics across the three sample groups, aiding both in risk stratification and predicting recurrence post-prostatectomy. The availability of such tool could have a broad impact across multiple cancers by enabling minimally invasive liquid biopsy sampling. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=67 SRC="FIGDIR/small/25325134v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@1a15b82org.highwire.dtl.DTLVardef@7ed263org.highwire.dtl.DTLVardef@26920corg.highwire.dtl.DTLVardef@3e7f0a_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Gravity-based microfiltration reveals unexpected prevalence of circulating tumor cell clusters in ovarian and colorectal cancer 93%
- Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define diagnostic and prognostic biosignatures for Parkinson’s Disease 91%
- Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer 90%
Similar papers in this journal
- Accurate prognosis for localized prostate cancer through coherent voting networks and multi-omic data 94%
- CD117/c-kit Represents a Prostate Cancer Stem-Like Subpopulation Driving Progression, Migration, and TKI Resistance 93%
- Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery 93%
Similar papers in this journal
- Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis 93%
- Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina 91%
- In vivo-mimicking 3D cultures secrete distinct extracellular vesicles upon cancer cell invasion 91%
Similar papers in this journal
- Circulating Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in 11C Choline-identified Oligometastatic Castration-Refractory Prostate Cancer Treated with Stereotactic Ablative Radiotherapy 96%
- Association Between Artificial Intelligence-Derived Tumor Volume and Oncologic Outcomes for Localized Prostate Cancer Treated with Radiation Therapy 89%
- ImmunoPET as Stoichiometric Sensor for Glypican-3 in Models of Hepatocellular Carcinoma 88%
Similar papers in this journal
- PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate Cancer Analysis from the STOMP-like and ORIOLE trial cohorts 93%
- Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer 93%
- Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.